Idec Zevalin
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA's Oncologic Drugs Advisory Committee will review the non-Hodgkin's lymphoma therapy ibritumomab tiuxetan Sept. 11. As a condition of approval, FDA has requested a Phase IV trial to study use of the antibody in patients previously exposed to murine-based anti-cancer therapies. Zevalin received a "complete review" letter May 3 (Pharmaceutical Approvals Monthly, June 2001, p. 16)
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.